US Patent 11944612 Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Patent 11944612 was granted and assigned to Global Blood Therapeutics on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+40 properties)
Article (+260 characters)
US Patent 11944612 Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Article
Patent abstract
Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Athiwat Hutchaleelaha0
Eleanor L. Ramos0
Joshua Eli Lehrer-Graiwer0
Naveen Bejugam0
Date of Patent
April 2, 2024
0Patent Application Number
178818740
Date Filed
August 5, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11944612 Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
